Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
04 févr. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
05 janv. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
17 déc. 2020 07h00 HE
|
Otonomy, Inc.
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing testsA single intratympanic injection of OTO-413 was well-tolerated Otonomy intends to...
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
30 nov. 2020 07h30 HE
|
Otonomy, Inc.
FDA’s review confirms use of Negative Binomial model for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease; results still expected in first quarter of 2021Company...
Otonomy to Participate in Two Upcoming Investor Conferences
16 nov. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update
04 nov. 2020 16h17 HE
|
Otonomy, Inc.
Enrollment completed in Phase 3 clinical trial of OTIVIDEX® in Ménière’s disease with results expected in the first quarter of 2021Positive results reported for Phase 1/2 clinical trial of OTO-313 in...
Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update
28 oct. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Growing Technological Developments in Hearing Amplifiers during COVID-19 Crisis to Augment the Growth of Hearing Amplifiers Market - Exclusive Report [245 pages] by Research Dive
14 oct. 2020 07h20 HE
|
Research Dive
New York, USA, Oct. 14, 2020 (GLOBE NEWSWIRE) -- The latest research report on the global hearing amplifiers market by Research Dive states the impact of the COVID-19 pandemic on the current and...
Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX® in Ménière’s Disease
02 oct. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in Four Upcoming Investor Conferences
02 sept. 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...